We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · April 23, 2015

Treatment Options for T2D Patients After Exenatide Twice Daily or Glimepiride + Metformin

Diabetes, Obesity & Metabolism


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Treatment Escalation Options for Patients With Type 2 Diabetes After Failure of Exenatide BID or Glimepiride Added to Metformin: Results From the Prospective European Exenatide (EUREXA) Study
Diabetes Obes Metab 2015 Apr 01;[EPub Ahead of Print], G Schernthaner, J Rosas-Guzmán, F Dotta, B Guerci, R Simó, A Festa, J Kiljański, M Zhou, B Gallwitz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading